Discover
KURA
Kura Oncology, Inc.
11.73
2 x 8.42
2 x 14.95
bid
ask
+
0.01
0.09%
2 @ 07:30 PM
11.73 +0.00 (0.00%)
| Ytd | 12.90% | |
| 1y | 38.98% |
11.56
day range
11.84
7.40
52 week range
13.59
| Open | 11.61 | Prev Close | 11.72 | Low | 11.56 | High | 11.84 | Mkt Cap | 1.04B |
| Vol | 2.67M | Avg Vol | 1.81M | EPS | -3.37 | P/E | N/A | Forward P/E | -5.11 |
| Beta | 0.43 | Short Ratio | 6.19 | Inst. Own | 99.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 11.18 | 200-d Avg | 9.81 | 1yr Est | 32.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.84 | N/A | N/A | N/A |
| 2026-08-12 | 2026-06 | -0.88 | -0.77 | 0.11 | 12.23% |
| 2026-05-12 | 2026-03 | -0.88 | -0.83 | 0.05 | 5.68% |
| 2026-03-05 | 2025-12 | -0.72 | -0.92 | -0.2 | -27.78% |
| 2025-11-04 | 2025-09 | -0.57 | -0.85 | -0.28 | -49.12% |
| 2025-08-07 | 2025-06 | 0.15 | -0.75 | -0.9 | -600.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-24 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-08-13 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-28 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-15 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-04-14 | Lake Street | Upgrade | Buy | |
| 2026-03-24 | Mizuho | Upgrade | Outperform | Outperform |
Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-18 | BAIR TERESA BROPHY | Officer | 195.44K | Sale |
| 2026-01-26 | BURROWS FRANCIS J. PH.D. | Officer | 32.42K | Sale |
| 2026-01-26 | DOYLE THOMAS JAMES | Officer | 145.67K | Sale |
| 2026-05-18 | FORD KATHLEEN | Chief Operating Officer | 153.56K | Sale |
| 2025-12-08 | HASNAIN FAHEEM | Director | 23.98K | Conversion of Exercise of derivative security |
| 2026-06-17 | LEONI MOLLIE M.D. | Officer | 182.35K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 10.51M | 123.27M | 11.81% |
| 2026-06-29 | Montanova Capital LLC | 8.58M | 100.59M | 9.64% |
| 2026-06-29 | BVF Inc. | 8.45M | 99.07M | 9.49% |
| 2026-06-29 | State Street Corporation | 5.33M | 62.51M | 5.99% |
| 2026-06-29 | Vanguard Capital Management LLC | 3.92M | 45.94M | 4.40% |
| 2026-06-29 | Armistice Capital, LLC | 3.68M | 43.14M | 4.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.02M | 35.43M | 3.40% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80M | 32.84M | 3.15% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 2.17M | 25.44M | 2.44% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.03M | 12.05M | 1.15% |
| 2026-06-29 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 921.60K | 10.81M | 1.04% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 Growth ETF | 780.46K | 9.15M | 0.88% |